title: Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
abstract: While the clinical benefit of MEK inhibitor (MEKi)-based therapy is well established in Raf mutant malignancies, its utility as a suppressor of hyperactive MAPK signaling in the absence of mutated Raf or Ras, is an area of ongoing research. MAPK activation is associated with loss of ERα expression and hormonal resistance in numerous malignancies. Herein, we demonstrate that MEKi induces a feedback response that results in ERα overexpression, phosphorylation and transcriptional activation of ER-regulated genes. Mechanistically, MEKi-mediated ERα overexpression is largely independent of erbB2 and AKT feedback activation, but is ERK-dependent. We subsequently exploit this phenomenon therapeutically by combining the ER-antagonist, fulvestrant with MEKi. This results in synergistic suppression of tumor growth, in vitro and potentiation of single agent activity in vivo in nude mice bearing xenografts. Thus, we demonstrate that exploiting adaptive feedback after MEKi can be used to sensitize ERα-positive tumors to hormonal therapy, and propose that this strategy may have broader clinical utility in ERα-positive ovarian carcinoma.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
authors: June Y
authors: JY
authors: Hou
authors: Alicia
authors: A
authors: Rodriguez-Gabin
authors: Leleesha
authors: L
authors: Samaraweera
authors: Leleesha
authors: L
authors: Samaweera
authors: Rachel
authors: R
authors: Hazan
authors: Gary L
authors: GL
authors: Goldberg
authors: Susan Band
authors: SB
authors: Horwitz
authors: Hayley M
authors: HM
authors: McDaid
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D025461:Feedback, Physiological / Q000187:drug effects; D005260:Female; D000077267:Fulvestrant; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology; D006801:Humans; D000077341:Lapatinib; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D006575:Heterocyclic Compounds, 3-Ring; C548887:MK 2206; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D000077267:Fulvestrant; D004958:Estradiol; C506614:mirdametinib; D004159:Diphenylamine; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D020930:MAP Kinase Kinase Kinases
references: Gynecol Oncol. 2007 Sep;106(3):461-8
references: 17624412
references: Cell Prolif. 2008 Dec;41(6):923-935
references: 19040570
references: Gynecol Oncol. 2006 Nov;103(2):703-8
references: 16828848
references: J Steroid Biochem Mol Biol. 1994 Jun;49(4-6):327-31
references: 8043496
references: Int J Breast Cancer. 2011;2011:232435
references: 22295213
references: Endocr Relat Cancer. 2005 Dec;12(4):851-66
references: 16322326
references: Clin Cancer Res. 2007 Jun 15;13(12):3617-22
references: 17575226
references: Clin Cancer Res. 2006 Jan 1;12(1):298-304
references: 16397055
references: Gynecol Oncol. 2011 Feb;120(2):185-8
references: 21075433
references: Gynecol Oncol. 2007 May;105(2):341-50
references: 17306348
references: Oncogene. 2013 Jul 25;32(30):3543-51
references: 22907427
references: Gynecol Oncol. 2008 Mar;108(3):510-4
references: 18155273
references: Steroids. 2003 Jan;68(1):1-9
references: 12475718
references: Nature. 2006 Jan 19;439(7074):358-62
references: 16273091
references: J Histochem Cytochem. 2007 May;55(5):505-13
references: 17242463
references: J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):219-30
references: 19815064
references: Science. 1995 Dec 1;270(5241):1491-4
references: 7491495
references: Endocr Rev. 1991 Feb;12(1):14-26
references: 1851084
references: Cancer Res. 2004 Oct 1;64(19):6915-8
references: 15466181
references: Int J Cancer. 1993 Sep 30;55(3):459-64
references: 8375930
references: Cancer Res. 2007 Dec 1;67(23):11300-8
references: 18056456
references: Clin Cancer Res. 2002 Jul;8(7):2233-9
references: 12114425
references: PLoS One. 2009;4(2):e4560
references: 19234599
references: Mol Cell Proteomics. 2009 Mar;8(3):467-80
references: 18984578
references: J Biol Chem. 1998 May 22;273(21):13317-23
references: 9582378
references: Br J Cancer. 1995 Sep;72(3):521-7
references: 7669555
references: J Oncol. 2010;2010:126295
references: 20445756
references: Gynecol Oncol. 1996 Jul;62(1):4-6
references: 8690289
references: Cancer Res. 2007 Feb 1;67(3):1352-60
references: 17283173
references: Pathol Oncol Res. 2011 Sep;17(3):551-9
references: 21136228
references: Oncogene. 2011 Jul 21;30(29):3261-73
references: 21358676
references: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7
references: 10318951
references: Gynecol Oncol. 2009 May;113(2):205-9
references: 19239974
references: FEBS Lett. 2010 Jan 4;584(1):124-8
references: 19925796
references: Clin Cancer Res. 2004 Oct 1;10(19):6432-6
references: 15475429
references: Mol Cancer Ther. 2012 Apr;11(4):805-16
references: 22319200
references: Gynecol Oncol. 2004 Jul;94(1):25-32
references: 15262115
references: Nature. 2010 Sep 30;467(7315):596-9
references: 20823850
references: Oncogene. 2002 Nov 21;21(53):8158-65
references: 12444551
references: Am J Surg Pathol. 2009 Aug;33(8):1220-4
references: 19461510
references: EMBO J. 2001 Jul 2;20(13):3484-94
references: 11432835
references: J Biol Chem. 2007 May 11;282(19):14056-64
references: 17360704
references: Gynecol Oncol. 2009 Sep;114(3):480-5
references: 19560192
references: Oncology. 2004;66(2):112-7
references: 15138362
references: J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
references: 12644542
references: Mol Cancer Ther. 2009 Sep;8(9):2526-36
references: 19755509
references: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references: 2359136
references: Clin Cancer Res. 2007 Dec 1;13(23):7029-36
references: 18056179
references: Cell Mol Life Sci. 2005 Dec;62(24):2910-5
references: 16374578
references: Biochim Biophys Acta. 1998 Aug 19;1378(1):F61-77
references: 9739760